A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy

BACKGROUND: The effective treatment of triple-negative breast cancer (TNBC) remains a profound clinical challenge. Despite frequent epidermal growth factor receptor (EGFR) overexpression and reliance on downstream signalling pathways in TNBC, resistance to EGFR-tyrosine kinase inhibitors (TKIs) rema...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res
Main Authors: McLaughlin, Ronan P., He, Jichao, van der Noord, Vera E., Redel, Jevin, Foekens, John A., Martens, John W. M., Smid, Marcel, Zhang, Yinghui, van de Water, Bob
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6604188/
https://ncbi.nlm.nih.gov/pubmed/31262335
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-019-1161-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados